Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
Huamin Li, Huai‐rong Xiang, Bei He, Qizhi Zhang, Wenxing Peng
Abstract
Background: The efficacy of nirmatrelvir plus ritonavir (NMV-r) for vaccinated COVID-19 patients at high risk of progression is not adequately recognised. To address this gap, we conducted a systematic review and meta-analysis of current literature. Methods: statistics. Results: = 23%). Conclusions: We found positive evidence for the use of NMV-r for vaccinated patients at high-risk of progression with mild to moderate COVID-19. However, large-scale RCTs are needed to confirm these findings. Registration: PROSPERO CRD42023391349.
Topics & Concepts
Meta-analysisMedicineRelative riskConfidence intervalCochrane LibraryCoronavirus disease 2019 (COVID-19)MEDLINEObservational studyInternal medicineIncidence (geometry)Cohort studySystematic reviewDiseaseBiologyInfectious disease (medical specialty)OpticsBiochemistryPhysicsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesBacterial Infections and Vaccines